Plus Therapeutics (PSTV) Interest Expenses (2011 - 2026)
Plus Therapeutics (PSTV) reported Interest Expenses of $17000.0 for Q1 2026, down 96.9% year-over-year from $548000.0 in Q1 2025, and down 96.9% quarter-over-quarter from $548000.0 in Q1 2025.
Plus Therapeutics (PSTV) Interest Expenses (2011 - 2026) Analysis & Trends
Plus Therapeutics (PSTV) has 16 years of Interest Expenses data on file, last reported at $17000.0 in Q1 2026.
- Interest Expenses for Q1 2026 came in at $17000.0, down 96.9% year-over-year; the trailing twelve-month figure through Mar 2026 was $17000.0 (down 97.55% YoY), and the FY2025 annual result was $548000.0, up 206.15% from the prior year.
- Interest Expenses declined to $17000.0 in Q1 2026 per PSTV's latest filing, from $548000.0 in the prior quarter.
- Over five years, Interest Expenses peaked at $548000.0 in Q1 2025 and troughed at $17000.0 in Q1 2026.
- A 5-year average of $130642.9 and a median of $99000.0 in 2022 frame the typical range for Interest Expenses.
- The sharpest annual moves came in 2025 and 2026: Interest Expenses soared 1511.76% in 2025, then plunged 96.9% in 2026.
- A 5-year view of Interest Expenses shows it stood at $111000.0 in 2022, then sank by 44.14% to $62000.0 in 2023, then retreated by 8.06% to $57000.0 in 2024, then surged by 861.4% to $548000.0 in 2025, then sank by 96.9% to $17000.0 in 2026.
- Business Quant data shows PSTV's Interest Expenses at $17000.0 in Q1 2026, $548000.0 in Q1 2025, and $57000.0 in Q4 2024.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Int Expense (Qtr) |
|---|---|---|---|---|---|
| 1 | Alterity Therapeutics | 719,706.53 Bn | 719,706.50 Bn | - | - |
| 2 | Belite Bio | 55,800.00 Bn | 55,800.00 Bn | - | - |
| 3 | Quantum Biopharma | 18,182.30 Bn | 18,182.29 Bn | - | - |
| 4 | Legend Biotech | 3,154.00 Bn | 3,153.71 Bn | 242.10 Mn | -5.50 Mn |
| 5 | Akari Therapeutics | 1,844.30 Bn | 1,844.29 Bn | - | 61,000.00 |
| 6 | Evaxion A | 1,567.96 Bn | 1,567.94 Bn | - | -332,000.00 |
| 7 | Psyence Biomedical | 251.43 Bn | 251.42 Bn | - | -2,753.00 |
| 8 | Vertex Pharmaceuticals | 112.56 Bn | 105.31 Bn | 2.59 Bn | - |
| 9 | Abivax | 94.37 Bn | 94.37 Bn | - | -5.58 Mn |
| 10 | Plus Therapeutics | 37.48 Mn | 22.37 Mn | - | 17,000.00 |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 17,000.00 |
| Mar 31, 2026 | 17,000.00 |
| Mar 31, 2025 | 548,000.00 |
| Mar 31, 2025 | 548,000.00 |
| Dec 31, 2024 | 57,000.00 |
| Dec 31, 2024 | 57,000.00 |
| Sep 30, 2024 | 61,000.00 |
| Sep 30, 2024 | 61,000.00 |
| Jun 30, 2024 | 27,000.00 |
| Jun 30, 2024 | 27,000.00 |
| Mar 31, 2024 | 34,000.00 |
| Mar 31, 2024 | 34,000.00 |
| Dec 31, 2023 | 62,000.00 |
| Dec 31, 2023 | 62,000.00 |
| Sep 30, 2023 | 87,000.00 |
| Sep 30, 2023 | 87,000.00 |
| Jun 30, 2023 | 112,000.00 |
| Jun 30, 2023 | 112,000.00 |
| Mar 31, 2023 | 134,000.00 |
| Mar 31, 2023 | 134,000.00 |